Sibutramine

On October 8, 2010, the U.S. Food and Drug Administration (FDA) asked Abbott Laboratories to voluntarily withdraw Meridia from the U.S. market, its weight loss drug Meridia (sibutramine) because of clinical trial data indicating an increased risk of cardiovascular adverse events, including heart attack and stroke, in the studied population. Abbott has agreed to voluntarily stop the marketing of Meridia in the United States.

Source: FDA

Other Sources

Drug Identification Guide

CDC Facts

CDC Addiction Info

CDC Overdose Stats

CDC Substance Treatment

Whitehouse Drug-Free Communities

Samhsa Workplace Programs

Drug-Free

Federal Register Codification